Q1 Earnings Forecast for ALLO Issued By HC Wainwright

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Allogene Therapeutics in a report released on Monday, June 2nd. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.27) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.14) EPS.

A number of other analysts have also recently commented on the stock. Royal Bank of Canada restated an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Citizens Jmp cut shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Robert W. Baird dropped their price target on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Finally, Truist Financial dropped their price target on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Stock Down 4.4%

Shares of ALLO stock traded down $0.06 during mid-day trading on Tuesday, reaching $1.29. 1,808,197 shares of the company's stock traded hands, compared to its average volume of 3,317,842. Allogene Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.78. The company has a market cap of $282.16 million, a P/E ratio of -0.83 and a beta of 0.60. The company's 50-day moving average price is $1.34 and its 200-day moving average price is $1.77.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.28) EPS for the quarter, meeting analysts' consensus estimates of ($0.28).

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ALLO. Cibc World Markets Corp bought a new position in Allogene Therapeutics during the 4th quarter valued at about $26,000. PAX Financial Group LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter valued at about $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Allogene Therapeutics during the 1st quarter valued at about $28,000. RPO LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter valued at about $31,000. Finally, Caption Management LLC purchased a new stake in shares of Allogene Therapeutics during the 4th quarter valued at about $32,000. Institutional investors own 83.63% of the company's stock.

Insider Buying and Selling at Allogene Therapeutics

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 61,757 shares of company stock worth $115,873. Company insiders own 13.20% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).